This week's deal between Affimed Therapeutics AG and Johnson & Johnson put the bispecific antibody space in the headlines once again, as the field took another step toward becoming as hot as antibody-drug conjugates, said Jeremy Bender, chief business officer of Sutro Biopharma Inc., which made news in December via its deal with Celgene Corp.